SEARCH

SEARCH BY CITATION

References

  • 1
    WHO. Fact Sheet N°311. Obesity and Overweight. World Health Organization, Geneva, 2013.
  • 2
    FAO, WFP, IFAD. The State of Food Insecurity in the World 2012. Food and Agriculture Organization of the United Nations: Rome, 2012.
  • 3
    Spence-Jones G. Overview of obesity. CCNQ 2003; 26: 8388.
  • 4
    WHO. The SuRF report 2. Surveillance of chronic disease risk factors: country-level data and comparable estimates. World Health Organization: Geneva, 2005.
  • 5
    Drewnowski A, Popkin BM. The nutrition transition: new trends in the global diet. Nutr. Rev. 1997; 55: 3143.
  • 6
    Fontaine KR, Redden DT, Wang C, Westfall AO, Allison DB. Years of life lost due to obesity. JAMA 2003; 289: 187193.
  • 7
    Haslam DW, James WP. Obesity. Lancet 2005; 366: 11971209.
  • 8
    Kopelman PG. Obesity as a medical problem. Nature 2000; 404: 635643.
  • 9
    Flegal KM, Graubard BI, Williamson DF, Gail MH. Cause-specific excess deaths associated with underweight, overweight, and obesity. JAMA 2007; 298: 20282037.
  • 10
    Anderson JW, Conley SB, Nicholas AS. One hundred pound weight losses with an intensive behavioral program: changes in risk factors in 118 patients with long-term follow-up. Am. J. Clin. Nutr. 2007; 86: 301307.
  • 11
    Ross R, Dagnone D, Jones PJ, Smith H, Paddags A, Hudson R, Janssen I. Reduction in obesity and related comorbid conditions after diet-induced weight loss or exercise-induced weight loss in men. A randomized, controlled trial. Ann. Intern. Med. 2000; 133: 92103.
  • 12
    Withrow D, Alter DA. The economic burden of obesity worldwide: a systematic review of the direct costs of obesity. Obes. Rev. 2011; 12: 131141.
  • 13
    European Commission Press Release. White paper on nutrition: commission proposes EU-wide efforts to tackle the obesity epidemic. 2007; IP/07/720: 31.05.2007
  • 14
    Galic S, Oakhill JS, Steinberg GR. Adipose tissue as an endocrine organ. Mol. Cell. Endocrinol. 2010; 316: 129139.
  • 15
    Dunmore SJ, Brown JE. The role of adipokines in beta-cell failure of type 2 diabetes. J. Endocrinol. 2013; 216: T37T45.
  • 16
    Lago F, Gomez R, Gomez-Reino JJ, Dieguez C, Gualillo O. Adipokines as novel modulators of lipid metabolism. Trends Biochem. Sci. 2009; 34: 500510.
  • 17
    Ahima RS, Lazar MA. Adipokines and the peripheral and neural control of energy balance. Mol. Endocrinol. 2008; 22: 10231031.
  • 18
    Gerdes S, Rostami-Yazdi M, Mrowietz U. Adipokines and psoriasis. Exp. Dermatol. 2011; 20: 8187.
  • 19
    Ciprandi G, Caimmi D, Raschetti R, Miraglia Del Giudice M, Salpietro C, Caimmi S, Castellazzi AM. Adipokines and their role in allergies. Int. J. Immunopathol. Pharmacol. 2011; 24: 1316.
  • 20
    Mattu HS, Randeva HS. Role of adipokines in cardiovascular disease. J. Endocrinol. 2013; 216: T17T36.
  • 21
    Paz-Filho G, Lim EL, Wong ML, Licinio J. Associations between adipokines and obesity-related cancer. Front. Biosci. 2011; 16: 16341650.
  • 22
    Heiker JT, Kosel D, Beck-Sickinger AG. Molecular mechanisms of signal transduction via adiponectin and adiponectin receptors. Biol. Chem. 2010; 391: 10051018.
  • 23
    Coppari R, Bjorbaek C. Leptin revisited: its mechanism of action and potential for treating diabetes. Nat. Rev. Drug Discov. 2012; 11: 692708.
  • 24
    Silverman GA, Bird PI, Carrell RW, Church FC, Coughlin PB, Gettins PG, Irving JA, Lomas DA, Luke CJ, Moyer RW, Pemberton PA, Remold-O'Donnell E, Salvesen GS, Travis J, Whisstock JC. The serpins are an expanding superfamily of structurally similar but functionally diverse proteins. Evolution, mechanism of inhibition, novel functions, and a revised nomenclature. J. Biol. Chem. 2001; 276: 3329333296.
  • 25
    Law RH, Zhang Q, McGowan S, Buckle AM, Silverman GA, Wong W, Rosado CJ, Langendorf CG, Pike RN, Bird PI, Whisstock JC. An overview of the serpin superfamily. Genome Biol. 2006; 7: 216.
  • 26
    Samad F, Yamamoto K, Loskutoff DJ. Distribution and regulation of plasminogen activator inhibitor-1 in murine adipose tissue in vivo. Induction by tumor necrosis factor-alpha and lipopolysaccharide. J. Clin. Invest. 1996; 97: 3746.
  • 27
    Chen X, Cushman SW, Pannell LK, Hess S. Quantitative proteomic analysis of the secretory proteins from rat adipose cells using a 2D liquid chromatography-MS/MS approach. J. Proteome Res. 2005; 4: 570577.
  • 28
    Zvonic S, Lefevre M, Kilroy G, Floyd ZE, DeLany JP, Kheterpal I, Gravois A, Dow R, White A, Wu X, Gimble JM. Secretome of primary cultures of human adipose-derived stem cells: modulation of serpins by adipogenesis. Mol. Cell. Proteomics 2007; 6: 1828.
  • 29
    Heiker JT, Kloting N, Kovacs P, Kuettner EB, Strater N, Schultz S, Kern M, Stumvoll M, Bluher M, Beck-Sickinger AG. Vaspin inhibits kallikrein 7 by serpin mechanism. Cell. Mol. Life Sci. 2013; 70: 25692583.
  • 30
    Hida K, Wada J, Zhang H, Hiragushi K, Tsuchiyama Y, Shikata K, Makino H. Identification of genes specifically expressed in the accumulated visceral adipose tissue of OLETF rats. J. Lipid Res. 2000; 41: 16151622.
  • 31
    Hida K, Wada J, Eguchi J, Zhang H, Baba M, Seida A, Hashimoto I, Okada T, Yasuhara A, Nakatsuka A, Shikata K, Hourai S, Futami J, Watanabe E, Matsuki Y, Hiramatsu R, Akagi S, Makino H, Kanwar YS. Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity. Proc. Natl. Acad. Sci. U. S. A. 2005; 102: 1061010615.
  • 32
    Shaker OG, Sadik NA. Vaspin gene in rat adipose tissue: relation to obesity-induced insulin resistance. Mol. Cell. Biochem. 2013; 373: 229239.
  • 33
    Kloting N, Berndt J, Kralisch S, Kovacs P, Fasshauer M, Schon MR, Stumvoll M, Bluher M. Vaspin gene expression in human adipose tissue: association with obesity and type 2 diabetes. Biochem. Biophys. Res. Commun. 2006; 339: 430436.
  • 34
    Teshigawara S, Wada J, Hida K, Nakatsuka A, Eguchi J, Murakami K, Kanzaki M, Inoue K, Terami T, Katayama A, Iseda I, Matsushita Y, Miyatake N, McDonald JF, Hotta K, Makino H. Serum vaspin concentrations are closely related to insulin resistance, and rs77060950 at SERPINA12 genetically defines distinct group with higher serum levels in Japanese population. J. Clin. Endocrinol. Metab. 2012; 97: E1202E1207.
  • 35
    Youn BS, Kloting N, Kratzsch J, Lee N, Park JW, Song ES, Ruschke K, Oberbach A, Fasshauer M, Stumvoll M, Bluher M. Serum vaspin concentrations in human obesity and type 2 diabetes. Diabetes 2008; 57: 372377.
  • 36
    Korner A, Neef M, Friebe D, Erbs S, Kratzsch J, Dittrich K, Bluher S, Kapellen TM, Kovacs P, Stumvoll M, Bluher M, Kiess W. Vaspin is related to gender, puberty and deteriorating insulin sensitivity in children. Int. J. Obes. (London) 2011; 35: 578586.
  • 37
    Kloting N, Kovacs P, Kern M, Heiker JT, Fasshauer M, Schon MR, Stumvoll M, Beck-Sickinger AG, Bluher M. Central vaspin administration acutely reduces food intake and has sustained blood glucose-lowering effects. Diabetologia 2011; 54: 18191823.
  • 38
    Saalbach A, Vester K, Rall K, Tremel J, Anderegg U, Beck-Sickinger AG, Bluher M, Simon JC. Vaspin – a link of obesity and psoriasis? Exp. Dermatol. 2012; 21: 309312.
  • 39
    Schultz S, Saalbach A, Heiker JT, Meier R, Zellmann T, Simon JC, Beck-Sickinger AG. Proteolytic activation of prochemerin by kallikrein 7 breaks an ionic linkage and results in C-terminal rearrangement. Biochem. J. 2013; 452: 271280.
  • 40
    Aust G, Richter O, Rohm S, Kerner C, Hauss J, Kloting N, Ruschke K, Kovacs P, Youn BS, Bluher M. Vaspin serum concentrations in patients with carotid stenosis. Atherosclerosis 2009; 204: 262266.
  • 41
    Hida K, Poulsen P, Teshigawara S, Nilsson E, Friedrichsen M, Ribel-Madsen R, Grunnet L, Lund SS, Wada J, Vaag A. Impact of circulating vaspin levels on metabolic variables in elderly twins. Diabetologia 2012; 55: 530532.
  • 42
    Breitfeld J, Tonjes A, Bottcher Y, Schleinitz D, Wiele N, Marzi C, Brockhaus C, Rathmann W, Huth C, Grallert H, Illig T, Bluher M, Kovacs P, Stumvoll M. Genetic variation in the vaspin gene affects circulating serum vaspin concentrations. Int. J. Obes. (London) 2013; 37: 861866.
  • 43
    Breitfeld J, Heiker JT, Bottcher Y, Schleinitz D, Tonjes A, Weidle K, Krause K, Kuettner EB, Scholz M, Kiess W, Strater N, Beck-Sickinger AG, Stumvoll M, Korner A, Bluher M, Kovacs P. Analysis of a rare functional truncating mutation rs61757459 in vaspin (SERPINA12) on circulating vaspin levels. J. Mol. Med. (Berl) 2013; 91: 12851292.
  • 44
    Meyer-Hoffert U, Wu Z, Sreseli R, Ziernig E, BartelsHari J, Schwarz T, Schroder JM. Purification and characterization of vaspin in human skin—a new epidermal serine protease inhibitor. Exp. Dermatol. 2008; 17: 285285.
  • 45
    Skytt A, Stromqvist M, Egelrud T. Primary substrate-specificity of recombinant human stratum-corneum chymotryptic enzyme. Biochem. Biophys. Res. Commun. 1995; 211: 586-589.
  • 46
    Zhou A, Carrell RW, Huntington JA. The serpin inhibitory mechanism is critically dependent on the length of the reactive center loop. J. Biol. Chem. 2001; 276: 2754127547.
  • 47
    Jeong E, Youn BS, Kim DW, Kim EH, Park JW, Namkoong C, Jeong JY, Yoon SY, Park JY, Lee KU, Kim MS. Circadian rhythm of serum vaspin in healthy male volunteers: relation to meals. J. Clin. Endocrinol. Metab. 2010; 95: 18691875.
  • 48
    Kovacs P, Miehle K, Sandner B, Stumvoll M, Bluher M. Insulin administration acutely decreases vaspin serum concentrations in humans. Obes. Facts 2013; 6: 8688.
  • 49
    Seeger J, Ziegelmeier M, Bachmann A, Lossner U, Kratzsch J, Bluher M, Stumvoll M, Fasshauer M. Serum levels of the adipokine vaspin in relation to metabolic and renal parameters. J. Clin. Endocrinol. Metab. 2008; 93: 247251.
  • 50
    Tan BK, Heutling D, Chen J, Farhatullah S, Adya R, Keay SD, Kennedy CR, Lehnert H, Randeva HS. Metformin decreases the adipokine vaspin in overweight women with polycystic ovary syndrome concomitant with improvement in insulin sensitivity and a decrease in insulin resistance. Diabetes 2008; 57: 15011507.
  • 51
    Perlmutter DH, Glover GI, Rivetna M, Schasteen CS, Fallon RJ. Identification of a serpin-enzyme complex receptor on human hepatoma cells and human monocytes. Proc. Natl. Acad. Sci. U. S. A. 1990; 87: 37533757.
  • 52
    Perlmutter DH, Joslin G, Nelson P, Schasteen C, Adams SP, Fallon RJ. Endocytosis and degradation of alpha 1-antitrypsin-protease complexes is mediated by the serpin-enzyme complex (SEC) receptor. J. Biol. Chem. 1990; 265: 1671316716.
  • 53
    Lundstrom A, Egelrud T. Stratum corneum chymotryptic enzyme: a proteinase which may be generally present in the stratum corneum and with a possible involvement in desquamation. Acta Derm. Venereol. 1991; 71: 471474.
  • 54
    Borgono CA, Michael IP, Komatsu N, Jayakumar A, Kapadia R, Clayman GL, Sotiropoulou G, Diamandis EP. A potential role for multiple tissue kallikrein serine proteases in epidermal desquamation. J. Biol. Chem. 2007; 282: 36403652.
  • 55
    Nylander-Lundqvist E, Back O, Egelrud T. IL-1 beta activation in human epidermis. J. Immunol. 1996; 157: 16991704.
  • 56
    Brattsand M, Egelrud T. Purification and characterization of interleukin 1 beta from human plantar stratum corneum. Evidence of interleukin 1 beta processing in vivo not involving interleukin 1 beta convertase. Cytokine 1998; 10: 506513.
  • 57
    Hansson L, Backman A, Ny A, Edlund M, Ekholm E, Ekstrand Hammarstrom B, Tornell J, Wallbrandt P, Wennbo H, Egelrud T. Epidermal overexpression of stratum corneum chymotryptic enzyme in mice: a model for chronic itchy dermatitis. J. Invest. Dermatol. 2002; 118: 444449.
  • 58
    Ny A, Egelrud T. Transgenic mice over-expressing a serine protease in the skin: evidence of interferon gamma-independent MHC II expression by epidermal keratinocytes. Acta Derm. Venereol. 2003; 83: 322327.
  • 59
    Ny A, Egelrud T. Epidermal hyperproliferation and decreased skin barrier function in mice overexpressing stratum corneum chymotryptic enzyme. Acta Derm. Venereol. 2004; 84: 1822.
  • 60
    Ekholm E, Egelrud T. Stratum corneum chymotryptic enzyme in psoriasis. Arch. Dermatol. Res. 1999; 291: 195200.
  • 61
    Brunetti L, Di Nisio C, Recinella L, Chiavaroli A, Leone S, Ferrante C, Orlando G, Vacca M. Effects of vaspin, chemerin and omentin-1 on feeding behavior and hypothalamic peptide gene expression in the rat. Peptides 2011; 32: 18661871.
  • 62
    Kim M-S, Youn B-S. WO Patent 2,011,138,977, 2011.
  • 63
    Yousef GM, Scorilas A, Magklara A, Soosaipillai A, Diamandis EP. The KLK7 (PRSS6) gene, encoding for the stratum corneum chymotryptic enzyme is a new member of the human kallikrein gene family – genomic characterization, mapping, tissue expression and hormonal regulation. Gene 2000; 254: 119128.
  • 64
    Kishi T, Soosaipillai A, Grass L, Little SP, Johnstone EM, Diamandis EP. Development of an immunofluorometric assay and quantification of human kallikrein 7 in tissue extracts and biological fluids. Clin. Chem. 2004; 50: 709716.
  • 65
    Breitfeld J, Tonjes A, Gast MT, Schleinitz D, Bluher M, Stumvoll M, Kovacs P, Bottcher Y. Role of vaspin in human eating behaviour. PLoS One 2013; 8: e54140.
  • 66
    Fu BD, Yamawaki H, Okada M, Hara Y. Vaspin cannot inhibit TNF-alpha-induced inflammation of human umbilical vein endothelial cells. J. Vet. Med. Sci. 2009; 71: 12011207.
  • 67
    Phalitakul S, Okada M, Hara Y, Yamawaki H. Vaspin prevents TNF-alpha-induced intracellular adhesion molecule-1 via inhibiting reactive oxygen species-dependent NF-kappaB and PKCtheta activation in cultured rat vascular smooth muscle cells. Pharmacol. Res. 2011; 64: 493500.
  • 68
    Li H, Peng W, Zhuang J, Lu Y, Jian W, Wei Y, Li W, Xu Y. Vaspin attenuates high glucose-induced vascular smooth muscle cells proliferation and chemokinesis by inhibiting the MAPK, PI3K/Akt, and NF-kappaB signaling pathways. Atherosclerosis 2013; 228: 6168.
  • 69
    Jung CH, Lee WJ, Hwang JY, Seol SM, Kim YM, Lee YL, Park JY. Vaspin protects vascular endothelial cells against free fatty acid-induced apoptosis through a phosphatidylinositol 3-kinase/Akt pathway. Biochem. Biophys. Res. Commun. 2011; 413: 264269.
  • 70
    Baden T, Yamawaki H, Saito K, Mukohda M, Okada M, Hara Y. Telmisartan inhibits methylglyoxal-mediated cell death in human vascular endothelium. Biochem. Biophys. Res. Commun. 2008; 373: 253257.
  • 71
    Yamawaki H, Saito K, Okada M, Hara Y. Methylglyoxal mediates vascular inflammation via JNK and p38 in human endothelial cells. Am. J. Physiol. Cell Physiol. 2008; 295: C1510C1517.
  • 72
    Phalitakul S, Okada M, Hara Y, Yamawaki H. Vaspin prevents methylglyoxal-induced apoptosis in human vascular endothelial cells by inhibiting reactive oxygen species generation. Acta Physiol (Oxf.) 2013; 209: 212219.
  • 73
    Phalitakul S, Okada M, Hara Y, Yamawaki H. A novel adipocytokine, vaspin inhibits platelet-derived growth factor-BB-induced migration of vascular smooth muscle cells. Biochem. Biophys. Res. Commun. 2012; 423: 844849.
  • 74
    Jung CH, Lee WJ, Hwang JY, Lee MJ, Seol SM, Kim YM, Lee YL, Kim HS, Kim MS, Park JY. Vaspin increases nitric oxide bioavailability through the reduction of asymmetric dimethylarginine in vascular endothelial cells. PLoS One 2012; 7: e52346.
  • 75
    Nakatsuka A, Wada J, Iseda I, Teshigawara S, Higashio K, Murakami K, Kanzaki M, Inoue K, Terami T, Katayama A, Hida K, Eguchi J, Ogawa D, Matsuki Y, Hiramatsu R, Yagita H, Kakuta S, Iwakura Y, Makino H. Visceral adipose tissue-derived serine proteinase inhibitor inhibits apoptosis of endothelial cells as a ligand for the cell-surface GRP78/voltage-dependent anion channel complex. Circ. Res. 2013; 112: 771780.
  • 76
    Nakatsuka A, Wada J, Iseda I, Teshigawara S, Higashio K, Murakami K, Kanzaki M, Inoue K, Terami T, Katayama A, Hida K, Eguchi J, Horiguchi CS, Ogawa D, Matsuki Y, Hiramatsu R, Yagita H, Kakuta S, Iwakura Y, Makino H. Vaspin is an adipokine ameliorating ER stress in obesity as a ligand for cell-surface GRP78/MTJ-1 complex. Diabetes 2012; 61: 28232832.
  • 77
    Wang YM, Wang WP, Wang LP, Lu QH, Zhou XH. Calorie control increased vaspin levels of serum and periepididymal adipose tissue in diet-induced obese rats in association with serum free fatty acid and tumor necrosis factor alpha. Chin. Med. J. (Engl.) 2010; 123: 936941.
  • 78
    Zhu X, Jiang Y, Shan PF, Shen J, Liang QH, Cui RR, Liu Y, Liu GY, Wu SS, Lu Q, Xie H, Liu YS, Yuan LQ, Liao EY. Vaspin attenuates the apoptosis of human osteoblasts through ERK signaling pathway. Amino Acids 2013; 44: 961968.
  • 79
    Kamio N, Kawato T, Tanabe N, Kitami S, Morita T, Ochiai K, Maeno M. Vaspin attenuates RANKL-induced osteoclast formation in RAW264.7 cells. Connect. Tissue Res. 2013; 54: 147152.
  • 80
    Gettins PG, Olson ST. Exosite determinants of serpin specificity. J. Biol. Chem. 2009; 284: 2044120445.
  • 81
    Dementiev A, Simonovic M, Volz K, Gettins PG. Canonical inhibitor-like interactions explain reactivity of alpha1-proteinase inhibitor Pittsburgh and antithrombin with proteinases. J. Biol. Chem. 2003; 278: 3788137887.
  • 82
    Dementiev A, Dobo J, Gettins PG. Active site distortion is sufficient for proteinase inhibition by serpins: structure of the covalent complex of alpha1-proteinase inhibitor with porcine pancreatic elastase. J. Biol. Chem. 2006; 281: 34523457.